DoD/BioPort Seeking Anthrax Vaccine Change To Safer Five-Dose IM Regimen
Executive Summary
Studies supporting approval of a five-dose intramuscular regimen for the anthrax vaccine could be available in two years, according to BioPort Corporation, which is conducting the studies on behalf of the Department of Defense.
You may also be interested in...
BioPort
Department of Defense renegotiates contract with Lansing, Mich.-based anthrax vaccine manufacturer BioPort, agreeing to pay $10.64 per dose, up from the previous $4.36 per dose (1"The Pink Sheet" July 26, p. 28). BioPort will also manufacture fewer doses, down to 5.3 mil. from 7.6 mil. The value of the new contract, which runs through 2005, is $49.8 mil., compared to $25.7 mil. under the old contract. In addition, DoD has agreed to make an advance payment of $18.7 mil. to the company so that it can pay its creditors
BioPort
Department of Defense renegotiates contract with Lansing, Mich.-based anthrax vaccine manufacturer BioPort, agreeing to pay $10.64 per dose, up from the previous $4.36 per dose (1"The Pink Sheet" July 26, p. 28). BioPort will also manufacture fewer doses, down to 5.3 mil. from 7.6 mil. The value of the new contract, which runs through 2005, is $49.8 mil., compared to $25.7 mil. under the old contract. In addition, DoD has agreed to make an advance payment of $18.7 mil. to the company so that it can pay its creditors
Anthrax Vaccine Product May Be Studied By DoD; Facility Being Renovated
A longitudinal cohort study to determine the efficacy of Lansing, Michigan-based Bioport's anthrax vaccine adsorbed would be conducted under a proposal by Army Surgeon General Ronald Blank.